Oligodendroglioma pseudoprogression after radiotherapy in a doga case report
A veterinarian is looking at a follow-up magnetic resonance imaging three months after treatment. The brain tumor they irradiated appears to have grown — measurably and unambiguously larger. The question they need to answer right now is whether that growth means the therapy failed or whether it means the therapy worked. That question is the focus of the entire lecture. The phenomenon at the center of this question is called pseudoprogression. Rancilio and colleagues define it as an increase in lesion size and contrast enhancement on magnetic resonance imaging occurring within one to six months after radiotherapy — an apparent worsening that reflects treatment-related tissue reaction rather than true tumor growth. In human neuro-oncology, the incidence ranges from roughly 9 to 30 percent depending on the series. The mechanism, as described by Hygino da Cruz and colleagues and Brandsma and colleagues, is local inflammation with edema and abnormal vascular permeability; those changes allow contrast to leak into tissue and produce the radiological appearance of a growing tumor. Some series have even found an association between pseudoprogression and improved survival — an active inflammatory response to treatment, it turns out, may accompany favorable outcomes. The clinical stakes are real.
If you misread pseudoprogression as true progression, you might abandon a therapy that's actually working or escalate treatment that the patient doesn't need. Despite being well documented in human oncology, pseudoprogression was essentially unreported in dogs before this case. The patient that Rancilio and colleagues describe is a 7-year-old spayed female French Bulldog presenting after three months of progressive left-sided craniofacial muscle wasting and episodes of compulsive left circling. On examination, the left masseter and temporalis muscles were diffusely and markedly atrophied — individual muscle bellies could not be palpated. The dog also had a right head tilt and right-sided facial paralysis. Neuroanatomical localization was multifocal, pointing strongly toward involvement of the left trigeminal nerve, among other regions. French Bulldogs are relevant here: brachycephalic breeds carry elevated glioma rates, which shaped the diagnostic thinking from the start. High-field magnetic resonance imaging at 1.5 Tesla revealed two separate intracranial lesions with strikingly different imaging signatures. The first, in the suprasellar region above the pituitary, was an intra-axial mass — meaning it arose from within the brain tissue itself — that was T1-hypointense, non-contrast-enhancing, and T2 hyperintense, measuring 17 by 12 by 14 millimeters. Given those characteristics and the breed, it was presumptively diagnosed as a glioma.
The second lesion was extra-axial, sitting at the left trigeminal nerve, T1 hyperintense and contrast-enhancing on post-gadolinium images, measuring 7.5 millimeters at its widest. Its location and enhancement pattern made it look like a trigeminal nerve sheath tumor — a peripheral nerve tumor, which is an entirely different entity. Two lesions, two apparent diagnoses. The team planned stereotactic radiotherapy, or SRT — a highly focused, image-guided radiation technique — for both. The prescription was 7 Gray per fraction over three consecutive weekdays, totaling 21 Gray, delivered with nine coplanar intensity-modulated radiotherapy fields verified before each fraction by cone-beam computed tomography. No planning target volume margin was applied because of the lesions' proximity to critical brainstem structures. Three months after completing stereotactic radiotherapy, the follow-up magnetic resonance imaging showed the suprasellar mass had grown from 17 millimeters to 24 millimeters at the longest diameter — a 41 percent increase — and now showed a new focal area of contrast enhancement. Using the Response Evaluation Criteria In Solid Tumors version one point zero for dogs, which is a standardized imaging-based method of measuring tumor size change, this was classified as progressive disease. The trigeminal lesion, by contrast, was qualitatively unchanged: 7.5 millimeters, stable in size, shape, and post-contrast signal.
So one lesion appeared to be progressing while the other sat still. That asymmetry mattered. The clinical team's response reflected the diagnostic uncertainty directly. Rather than immediately re-irradiating or operating, they continued medical management, using glucocorticoids as both symptom control and a diagnostic probe. Steroids reduce radiation-associated inflammation and edema, so if the enlargement was pseudoprogression rather than true tumor growth, you'd expect the mass to shrink. By the seven-month recheck, that is exactly what happened. The suprasellar lesion had decreased to 18 millimeters — a reduction back toward baseline — and no longer demonstrated contrast enhancement. The Response Evaluation Criteria classified this as stable disease. The trigeminal lesion remained stable. The shrinkage after steroid exposure is a central piece of evidence for pseudoprogression. However, Rancilio and colleagues preserve the diagnostic uncertainty rather than declaring a verdict; the imaging story could still be consistent with other explanations. Then, at nine months, both lesions enlarged again. New vestibular signs had developed. The team prescribed a second course of stereotactic radiotherapy: 8 Gray times three fractions for a total of 24 Gray, with prednisone raised back to 0.5 milligrams per kilogram per day.
The dog lived 16 months from the start of the first radiotherapy course before being euthanized because of declining quality of life — a survival time consistent with the reported range of roughly 11 to 21 months for presumed intracranial gliomas in dogs. Necropsy produced two results that reframe the entire case. First, histopathology confirmed that the transient enlargement at three months was indeed pseudoprogression. Gross and microscopic examination documented extensive edema and necrosis consistent with post-treatment effects, and the early enlargement followed by partial regression fits that interpretation. Second, and more striking: both lesions — the suprasellar mass and the trigeminal nerve lesion — were of the same tumor type. Both were oligodendrogliomas. An oligodendroglioma is a glial tumor arising from oligodendrocytes, the myelin-producing cells of the central nervous system. The neoplastic cells in the trigeminal nerve and ganglion closely resembled those in the primary mass: polygonal cells in sheets, cords, and pseudorosettes, with 16 mitotic figures counted in 2.4 square millimeters. Immunohistochemistry showed moderate to strong Olig2 positivity in neoplastic cells, while glial fibrillary acidic protein — GFAP, a marker of a different glial cell type — was negative within the tumor. The presumed nerve sheath tumor was not a peripheral nerve tumor at all.
It was oligodendroglioma extending into the trigeminal nerve, a location that has never previously been described in dogs and has only about 16 reported cases even in human medicine. That diagnostic surprise underscores a core technical challenge: conventional magnetic resonance imaging cannot reliably distinguish pseudoprogression from true progression or from a third entity, late radiation necrosis — which refers to tissue death from radiation that occurs six months or more after treatment, as opposed to the earlier pseudoprogression window of one to six months. In this case, the suprasellar enlargement at three months falls squarely within the pseudoprogression window, while the second wave of growth at nine months sits in the later territory where late necrosis and true progression both become plausible. Timing alone is therefore necessary but not sufficient for diagnosis. In human neuro-oncology, molecular markers help refine the probability. MGMT promoter methylation — a modification that silences a DNA repair gene and makes tumors more vulnerable to treatment — is associated with higher pseudoprogression rates in glioblastoma. IDH-1 mutations are a common driver in human oligodendroglioma and can occur in dogs, but IDH-1 testing is not widely available in veterinary practice.
Rancilio and colleagues note that pseudoprogression has been reported in both IDH-1 mutant and wild-type oligodendrogliomas, so the molecular picture does not cleanly resolve the question. For now, the practical tool is a glucocorticoid trial combined with close serial imaging. Two findings from this case change how veterinary neuro-oncologists should approach post-treatment monitoring. First, pseudoprogression after radiotherapy is now histologically confirmed in a dog with oligodendroglioma. When a canine glioma patient shows early post-treatment imaging progression — especially within that one to six month window — pseudoprogression must be on the differential before concluding therapy has failed. In human patients, this happens in up to 30 percent of cases; the veterinary literature had essentially no documented examples until this report. Second, oligodendroglioma can involve the trigeminal nerve in dogs. Concurrent intracranial lesions with different imaging appearances should not be assumed to be different tumor types. The practical upshot: serial imaging interpreted in clinical context, awareness of the pseudoprogression time window, and a glucocorticoid trial as a first-line diagnostic and temporizing step. What looks like failure may not be. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.
Credits
- Source: Oligodendroglioma pseudoprogression after radiotherapy in a dog: a case reportNicholas J. Rancilio, Mary Drozd, Logan Donaldson, Tyler Harm, Keiko MurakamiFrontiers in Veterinary Science, 2025DOI: 10.3389/fvets.2025.1572808CC-BY
AI-generated lecture by ennepō.ai, adapted from the source above — restructured, summarized and explained. Not endorsed by the authors.
This lecture © ennepō.ai. See our Terms of Service.
Related lectures
- Navigating Maternal Mental Health: Weaning, Breastfeeding, and Emotional Wellbeing
- Polyamine transporter potABCD is required for virulence of encapsulated but not nonencapsulated Streptococcus pneumoniae
- Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans
- Global expansion and redistribution of Aedes-borne virus transmission risk with climate change
- Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020
- Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001–2018